A unique HIV cure case will be among the scientific highlights of AIDS 2024, the 25th International AIDS Conference, which will take place in Munich, Germany and virtually from 22 to 26 July. For the first time, scientists will share information about the “next Berlin Patient”, who appears to be...

First-of-its-kind HIV Cure Case Among Scientific Highlights at AIDS 2024

An overview of the complex relationships between herpes simplex virus, human papillomavirus, cytomegalovirus and HIV. Chronic viral infections from diseases such as between herpes simplex virus (HSV), human papillomavirus (HPV) and cytomegalovirus (CMV) can have a serious impact on those with immune systems already compromised by HIV, according to a session held today at the International AIDS Conference in Munich, Germany. The session featured three speakers who discussed each of these diseases.

Chronic Viral Infections Common in Those with HIV | AIDS 2024

EBT-101, a CRISPR-based gene-editing therapy, was safe and well tolerated in an early study, but it did not prevent viral rebound in the first four participants who interrupted antiretroviral treatment, according to a report at the International AIDS Conference (#AIDS2024) in Munich. One person, however, did see a decline in his HIV reservoir, and viral rebound was delayed for four months.

CRISPR Gene Therapy Does Not Prevent HIV Rebound

Therapeutic proteins have been increasingly used in recent years to treat cancer, HIV, and other diseases. A challenge with these types of drugs is that the release is rapid and thus the medicine must be administered frequently. Remco Tuinier, Professor of Physical Chemistry at Eindhoven University of Technology (TU/e), and...

New method enables gradual release of protein drugs into the body

Strong bones help maintain mobility and enhance quality of life. People with HIV are more prone to bone loss and fractures, but you can take steps to improve bone health. Bone is living tissue largely made up of minerals and collagen. Cells called osteoblasts continually add new bone tissue, while osteoclasts dissolve old bone. As people age, bone resorption starts to outpace bone formation, and bone mass naturally declines. Osteopenia is an earlier stage of bone loss, which can progress to osteoporosis.

HIV and Your Bones

HIV stigma in health care is real and harmful. Fortunately, health care providers can now take the antiviral drug Stigmavir to treat their stigma. Unfortunately, the drug is fictitious, but you can watch a real ad for it on YouTube. Casey House, an AIDS service provider in Toronto, created the...

Stigmavir to Treat HIV Stigma?

Despite rising trends in respiratory syncytial virus (RSV) testing, more outpatient testing is needed for accurate RSV surveillance. Since 2015, respiratory syncytial virus (RSV) testing among infants has increased across all health care settings and sociodemographic groups. However, outpatient testing remains disproportionately low.1. The results of the real-time clinical and...

RSV Testing Among Infants With Bronchiolitis Is Increasing, Study Shows

The Opt-Out scheme in Nottingham has already found a number of previously undiagnosed cases.

Hundreds tested for HIV and hepatitis in new scheme

Cover: Long-term survivor Bishop Stacey S. Latimer shares his advice on aging with HIV. Inside: Twice-yearly PrEP for women; HIV and your bones. Plus: Mark S. King questions his life-long fixation on survival.

POZ September 2024

People who start antiretroviral therapy (ART) during acute HIV infection experience a faster decline in the viral reservoir in CD4 T cells. Within days after infection, the virus inserts its genetic blueprints into the DNA of host cells and establishes a long-lasting reservoir that is unreachable by antiretro-virals. Using more than 500 blood samples from 67 people in the UCSF Treat Acute HIV cohort who started ART within 100 days after infection, researchers developed mathematical models of HIV dynamics and control. The models showed a biphasic decay of integrated proviral DNA out to one year. During the first phase, lasting up to five weeks, there was a steep decrease in intact HIV DNA, followed by a slower decline during the second phase. For every week ART was delayed, the half-life of intact proviral DNA was about 14 hours longer during the first phase and eight days longer during the second phase. While even very early treatment usually doesn’t prevent viral rebound after stopping anti-retrovirals, a smaller reservoir could improve prospects for a functional cure.

Cure: Smaller Reservoir

There are a ton of health tests available, but which medical tests do you really need? As you get older, that answer changes. Here are 12 to be aware of. Ladies, when it comes to your well-being, be proactive! Eat right, stay active, avoid tobacco, and have the following medical tests for women over 50 run to determine the state of your health. Doing so can help diagnose life-threatening diseases before damage or disabilities occur. If caught early, changes to your diet and lifestyle can often slow the progression and even reverse many of the chronic and age-related conditions that plague women in their prime.

12 Essential Medical Tests for Women Over 50

The Marijuana Herald

The Marijuana Herald - Marijuana news and information
A new study, published in the World Journal of Clinical Oncology, reveals that psilocybin may significantly improve the quality of life for patients with advanced cancer. The study, conducted by researchers from the University of Michigan and the University of New Mexico and published online by the US National Library of Medicine, highlights the compound’s … 
Continue reading
The post Study Finds Psilocybin Offers Significant Relief for Advanced Cancer Patients appeared first on The Marijuana Herald.

Study Finds Psilocybin Offers Significant Relief for Advanced Cancer Patients

A single shot of an experimental injection dramatically reduces levels of the monkey form of HIV in nonhuman primates for at least 30 weeks, according to a study published today in Science. The new research suggests that the lab-made shot has the potential to offer a simple and durable alternative to the current standard treatment for people living with HIV, which is effective but demanding.

New HIV Treatment Approach Shows Promise in Monkeys

Tampa, FL

Approval of neffy marks a significant advancement in epinephrine delivery, offering a less painful alternative to traditional needle injections. The FDA has approved ARS Pharmaceuticals’ neffy (epinephrine nasal spray), a first-in-class needle-free, nasal spray treatment for type I allergic reactions, such as anaphylaxis, for adults and children weighing 66 lbs. or more. According to the company, this approval offers a less painful alternative to traditional needle injections, which are often delayed due to anxiety, potentially worsening allergic reactions.1.

FDA Approves First Epinephrine Nasal Spray for Type I Allergic Reactions Including Anaphylaxis

Colorado State

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

David Heitz

A bill quietly introduced this spring in the Colorado legislature to decriminalize the possession of drug paraphernalia obtained by harm reductionists has become law. As low-key as the legislation was introduced, the bill was signed into law without fanfare June 6. It garnered little to no media attention.

Colorado legalizes needles, pipes for meth and crack if obtained by harm reduction group

Projections from an agent-based model based on data from Ontario, Canada, suggest both current and prospective strategies may not meet World Health Organization HCV goals. Current prevention, screening, and treatment strategies will not be sufficient to fully meet the World Health Organization (WHO) goals for reducing hepatitis C virus (HCV) incidence and deaths, according to findings from a recent study.1.

Current HCV Screening, Treatment Strategies Projected to Fall Short of WHO Goals

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed. Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, August 05 - Friday, August 09, 2024), and click each link to read and watch anything you may have missed.

Contemporary OB/GYN week in review: Abortion restrictions, STI testing, and more

The U.S. Food and Drug Administration (FDA) has approved the world’s first nasal spray drug, neffy (epinephrine nasal spray), for the treatment of Type I anaphylaxis. Approved on August 9, 2024, this adrenaline nasal spray offers a new option for treating severe allergic reactions in adults and pediatric patients weighing at least 30 kg. Further, this approval introduces a significant alternative for patients who delay treatment due to an aversion to injections.

The First-Ever Nasal Spray for Anaphylactic Shock Gets FDA Approval

Lenacapavir (Sunlenca), Gilead Sciences’ twice-yearly capsid inhibitor, demonstrated 100% efficacy for HIV prevention in a large study of young cisgender women in Africa. Oral PrEP is highly effective for people who can take it consistently, but additional options are still needed for people who have difficulty using daily pills. The Phase III PURPOSE 1 trial enrolled more than 5,300 women in South Africa and Uganda. They were randomly assigned to receive injectable lenacapavir once every six months or the daily PrEP pills Descovy (tenofovir alafenamide/emtricitabine) or Truvada (tenofovir disoproxil fumarate/emtricitabine) in a 2:2:1 ratio. There were zero new infections in the lenacapavir group, 39 in the Descovy group and 16 in the Truvada group. All three PrEP methods were well tolerated, and no new safety concerns were identified. A parallel study (PURPOSE 2) is testing lenacapavir PrEP for cisgender and transgender men, trans women and nonbinary people in the United States and six other countries; results are expected in late 2024 or early 2025.

Prevention: Twice-Yearly PrEP

Denver, CO

In addition to collecting more than 8,000 used needles in the past year from Denver drug users, the Harm Reduction Action Center passed out 10,000 meth pipes and “snort kits,” according to a newsletter sent to its supporters Thursday. They also connected about 1,700 people to medical, mental health and substance abuse treatment.

Denver group hands out 10K meth pipes, ‘snort kits,’ connects 1,700 to treatment annually

NewsBreak

Novel HIV Vaccine Approaches

Traditional vaccine approaches have not been able to prevent HIV, but researchers are exploring more sophisticated strategies. One novel approach, known as germline targeting, trains the...

Novel HIV Vaccine Approaches

Comments / 0